The latest price target for Annovis Bio (NYSE:ANVS) was reported by D. Boral Capital on November 11, 2024. The analyst firm set a price target for $21.00 expecting ANVS to rise to within 12 months (a possible 384.99% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Annovis Bio (NYSE:ANVS) was provided by D. Boral Capital, and Annovis Bio maintained their buy rating.

The last upgrade for Annovis Bio Inc happened on October 25, 2024 when Maxim Group raised their price target to $25. Maxim Group previously had a hold for Annovis Bio Inc.

The last downgrade for Annovis Bio Inc happened on February 28, 2024 when Brookline Capital changed their price target from N/A to $9 for Annovis Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Annovis Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Annovis Bio was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Annovis Bio (ANVS) rating was a maintained with a price target of $21.00 to $21.00. The current price Annovis Bio (ANVS) is trading at is $4.33, which is out of the analyst’s predicted range.